COMPANY
HISTORY
10 MOU for AST-203 Joint Development (Kolon Pharma)
10 AST-201 IND approval by Ministry of Food and Drug Safety
08 Rights offering for R&D
03 Joint Development Agreement for Radiopharmaceutical Therapy (Yonsei University Health System)
01 Starting AptoDetect™-Lung prescriptions at the general hospital as non-benefit
05 Joint Development Agreement of ApDC Targeted Agent (HicellTech)
04 Initiation of AptoDetect™-Lung multi-center prospective clinical trial
03 Immunetherapy AST-202 Study Data Announcement (AACR 2023)
11 The grant supported by the Korea Drug Development Fund, KDDF (CD25-ApDC)
10 Issuance of non-guaranteed privately placed convertible bonds
06 AptoDetectTM-Lung designated as the Postponement of New Health Technology Assessment from the NECA.
04 AST-201 CDMO contract (Asymchem inc)
03 Joint Development Agreement for Parkinson's Disease Treatment(Neuramedy Co.,Ltd)
08 The integration of headquarters and aptamer synthesis facilities (Pangyo Seven Venture Valley)
06 The agreement of co-development on targeted anticancer therapeutics with PINOTBIO
05 The grant supported by the Korea Drug Development Fund, KDDF for the non-clinical development of COVID-19 treatment
![[2021]년도 이미지](https://aptsci.com/data/bbsData/16388458831.jpg)
09 Listed on the KOSDAQ market
04 The grant supported by the Ministry of Health and Welfare (KRW 1.67 billion) for the pre-clinical development of Diabetes treatment
02 MOU with NEURAMEDY for the development of Parkinson’s disease treatment
![[2020]년도 이미지](https://aptsci.com/data/bbsData/16388458721.jpg)
12 The agreement on the supply of AptoDetect™-Lung to Singapore and clinical trials (BIOMED, TTSH Hospital)
03 The relocation of the head office (Seoul National University Bundang Hospital Healthcare Innovation Park)
11 The ISO13485/CE certification and an agreement with China BGT on the supply of AptoDetect™-Lung.
09 The MTA with Novo Nordisk on the development of novel allosteric aptamers for diabetes.
![[2018]년도 이미지](https://aptsci.com/data/bbsData/16403292361.jpg)
09 The approval for the manufacture of AptoDetect™-Lung from the Ministry of Food and Drug Safety.
![[2017]년도 이미지](https://aptsci.com/data/bbsData/16390148151.jpg)
12 The grant supported by the Korea Drug Development Fund, KDDF (first-in-class drugs for diabetes, J&J joint cooperative project)
07 The relocation of the corporate R&D center (Seoul National University Bundang Hospital Healthcare Innovation Park)
01 GMP certification for in vitro diagnostic class III medical device from the Ministry of Food and Drug Safety.
07 Manufacturing and sales approval for medical devices and the product of lung cancer IVD for export from the Ministry of Food and Drug Safety
09 Started the operation of the diagnostic laboratory in ASAN Medical Center and initiated the cooperation on clinical development of lung cancer IVD Kit for in vitro diagnostic use
06 The start-up growth grant supported by the Small and Medium Business Administration (SMBA) (development of cancer and vascular endothelial cell separation kit)
12 The establishment of a multi-diagnostic technology platform
06 The cooperative agreement on the discovery of aptamers with NOVATIS
05 The licensing agreement on aptamer technology with POSTECH
04 The establishment of Aptamer Sciences Inc. (POSTECH spin-off)
![[2011]년도 이미지](https://aptsci.com/data/bbsData/16390147961.jpg)